DDrare: Database of Drug Development for Rare Diseases

He3286 (DrugBank: HE3286)

2 diseases

ID	Disease name (Link within this page)	Number of trials
46	Malignant rheumatoid arthritis	1
97	Ulcerative colitis	1

46. Malignant rheumatoid arthritis [ 4,183 clinical trials, 2,538 drugs, (DrugBank: 401 drugs), 183 drug target genes, 219 drug target pathways]

Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 4,183 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00712114 (ClinicalTrials.gov)	July 2008	6/7/2008	Safety, Tolerance, Pharmacokinetics and Activity of HE3286 in Patients With Rheumatoid Arthritis	A Phase I/II, Open Label, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Potential Anti-Inflammatory Activity of HE3286 When Administered Orally for 29 Days to Patients With Rheumatoid Arthritis on a Stable Dose of Methotrexate	Rheumatoid Arthritis	Drug: HE3286	Harbor Therapeutics	NULL	Completed	18 Years	75 Years	Both	14	Phase 1;Phase 2	United States

97. Ulcerative colitis [ 2,269 clinical trials, 1,331 drugs, (DrugBank: 241 drugs), 114 drug target genes, 181 drug target pathways]

Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 2,269 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00628433 (ClinicalTrials.gov)	February 2008	25/2/2008	Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis	A Phase I/II, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Activity of HE3286 When Administered Orally to Patients With Active, Mild-to-Moderate Ulcerative Colitis	Ulcerative Colitis	Drug: Placebo;Drug: HE3286	Harbor Therapeutics	NULL	Completed	18 Years	65 Years	Both	27	Phase 1;Phase 2	United States